The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD

Fatima Amanat; Mahima Thapa; Tingting Lei; Shaza M. Sayed Ahmed; Daniel C. Adelsberg; Juan Manuel Carreno; Shirin Strohmeier; Aaron J. Schmitz; Sarah Zafar; Julian Q Zhou; Willemijn Rijnink; Hala Alshammary; Nicholas Borcherding; Ana Gonzalez Reiche; Komal Srivastava; Emilia Mia Sordillo; Harm van Bakel; Jackson S. Turner; Goran Bajic; Viviana M Simon; Ali H. Ellebedy; Florian Krammer.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-21253098

Documentos relacionados

  1. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2.
  2. The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD.
  3. T cell responses to SARS-CoV-2 spike cross-recognize Omicron.
  4. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
  5. High-resolution map of the Fc functions mediated by COVID-19-neutralizing antibodies.
  6. SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency.
  7. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting.
  8. Circular RNA vaccines against SARS-CoV-2 and emerging variants.
  9. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines.
  10. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape.